Genome-Wide Promoter Methylome of Small Renal Masses

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Ibragimova, Ilsiya ^a   Slifker, Michael J ^a   Maradeo, Marie E ^a   Banumathy, Gowrishankar ^a   Dulaimi, Essel ^a   Uzzo, Robert G ^a   Cairns, Paul ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOPHOBE RENAL CELL CARCINOMA; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; ONCOCYTOMA; PAPILLARY RENAL CELL CARCINOMA; PROMOTER REGION; SMALL RENAL MASS;

ADENOMA, OXYPHILIC; AGED; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROMOTER REGIONS, GENETIC;

EID: 84886245391     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077309     Document Type: Article

References (75)

1. Simard EP, Ward EM, Siegel R, Jemal A (2012) Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin: 118-128.
2. Siegel R, Naishadham D, Jemal A, (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
3. Cairns P, (2010) Renal cell carcinoma. Cancer Biomark 9: 461-473.
4. Corcoran AT, Russo P, Lowrance WT, Asnis-Alibozek A, Libertino JA, et al. (2013) A Review of Contemporary Data on Surgically Resected Renal Masses-Benign or Malignant? Urology 81: 707-713.
5. McKiernan J, Yossepowitch O, Kattan MW, Simmons R, Motzer RJ, et al. (2002) Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology 60: 1003-1009.
6. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, et al. (2003) Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 170: 2217-2220.
7. Gill IS, Matin SF, Desai MM, Kaouk JH, Steinberg A, et al. (2003) Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. J Urol 170: 64-68.
8. Jones PA, Baylin SB, (2007) The epigenomics of cancer. Cell 128: 683-692.
9. Esteller M, (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
10. Hoffman AM, Cairns P, (2011) Epigenetics of kidney cancer and bladder cancer. Epigenomics 3: 19-34.
11. Arai E, Chiku S, Mori T, Gotoh M, Nakagawa T, et al. (2012) Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Carcinogenesis 33: 1487-1493.
12. Ricketts CJ, Morris MR, Gentle D, Brown M, Wake N, et al. (2012) Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics 7: 278-290.
13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, et al. (2009) Chapter 43 Kidney. AJCC Cancer Staging Manual Seventh Edition: 479-490.
14. Sambrook J, Russell DW (2001) Preparation and Analysis of Eukaryotic Genomic DNA. In: Molecular Cloning A Laboratory Manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.
15. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
16. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA, (2003) Identifying biological themes within lists of genes with EASE. Genome Biol 4: R70.
17. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
18. TCGA (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
19. Delahunt B, Eble JN, (1997) Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10: 537-544.
20. Al-Saleem T, Cairns P, Dulaimi EA, Feder M, Testa JR, et al. (2004) The genetics of renal oncocytosis: a possible model for neoplastic progression. Cancer Genet Cytogenet 152: 23-28.
21. Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, et al. (2002) Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 26: 1542-1552.
22. Yusenko MV, (2010) Molecular pathology of renal oncocytoma: a review. Int J Urol 17: 602-612.
23. Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, et al. (2012) Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res 22: 271-282.
24. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, et al. (1999) CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96: 8681-8686.
25. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, et al. (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787-793.
26. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
27. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, et al. (2011) Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med 3: 75ra25.
28. TCGA (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499: 43-49.
29. McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, et al. (2009) CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer 8: 31.
30. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, et al. (2009) Genome-wide DNA methylation profiling using Infinium(R) assay. Epigenomics 1: 177-200.
31. Esteller M, Corn PG, Baylin SB, Herman JG, (2001) A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229.
32. Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, et al. (2004) Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 10: 3972-3979.
33. Smits KM, Schouten LJ, van Dijk BA, Hulsbergen-van de Kaa CA, Wouters KA, et al. (2008) Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis. Clin Cancer Res 14: 782-787.
34. Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruine AP, et al. (2008) Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta 1785: 133-155.
35. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, et al. (2011) Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43: 442-446.
36. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, et al. (2012) Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44: 133-139.
37. Ilhan A, Neziri D, Maj M, Mazal PR, Susani M, et al. (2011) Expression of secretagogin in clear-cell renal cell carcinomas is associated with a high metastasis rate. Hum Pathol 42: 641-648.
38. Costa VL, Henrique R, Ribeiro FR, Pinto M, Oliveira J, et al. (2007) Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer 7: 133.
39. Dahl E, Wiesmann F, Woenckhaus M, Stoehr R, Wild PJ, et al. (2007) Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene 26: 5680-5691.
40. Slater AA, Alokail M, Gentle D, Yao M, Kovacs G, et al. (2013) DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma. Epigenetics 8.
41. Linehan WM, Srinivasan R, Schmidt LS, (2010) The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7: 277-285.
42. Riss J, Khanna C, Koo S, Chandramouli GV, Yang HH, et al. (2006) Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res 66: 7216-7224.
43. Thiery JP, Acloque H, Huang RY, Nieto MA, (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
44. Banumathy G, Cairns P, (2010) Signaling pathways in renal cell carcinoma. Cancer Biol Ther 10: 658-664.
45. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, et al. (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39: 237-242.
46. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, et al. (2007) Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39: 232-236.
47. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, et al. (2007) Epigenetic stem cell signature in cancer. Nat Genet 39: 157-158.
48. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, et al. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125: 301-313.
49. Easwaran H, Johnstone SE, Van Neste L, Ohm J, Mosbruger T, et al. (2012) A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res 22: 837-849.
50. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, et al. (2007) Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 7: 246-255.
51. Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, et al. (2010) Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res 70: 4460-4469.
52. De Carvalho DD, Sharma S, You JS, Su SF, Taberlay PC, et al. (2012) DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 21: 655-667.
53. Kagara I, Enokida H, Kawakami K, Matsuda R, Toki K, et al. (2008) CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. J Urol 180: 343-351.
54. ten Klooster JP, Hordijk PL, (2007) Targeting and localized signalling by small GTPases. Biol Cell 99: 1-12.
55. He H, Ding F, Li Y, Luo A, Chen H, et al. (2012) Migfilin regulates esophageal cancer cell motility through promoting GSK-3beta-mediated degradation of beta-catenin. Mol Cancer Res 10: 273-281.
56. Takai D, Jones PA, (2002) Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 99: 3740-3745.
57. The Illumina Body Map data (2011) Available: http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-513/.Accessed 2013 Sept 12.
58. Zeller C, Dai W, Curry E, Siddiq A, Walley A, et al. (2013) The DNA methylomes of serous borderline tumors reveal subgroups with malignant- or benign-like profiles. Am J Pathol 182: 668-677.
59. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, et al. (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360-363.
60. Greenfield A, Carrel L, Pennisi D, Philippe C, Quaderi N, et al. (1998) The UTX gene escapes X inactivation in mice and humans. Hum Mol Genet 7: 737-742.
61. Tsuchiya KD, Greally JM, Yi Y, Noel KP, Truong JP, et al. (2004) Comparative sequence and x-inactivation analyses of a domain of escape in human Xp11.2 and the conserved segment in mouse. Genome Res 14: 1275-1284.
62. Slawson C, Hart GW, (2011) O-GlcNAc signalling: implications for cancer cell biology. Nat Rev Cancer 11: 678-684.
63. Deaton AM, Bird A, (2011) CpG islands and the regulation of transcription. Genes Dev 25: 1010-1022.
64. Youssef YM, White NM, Grigull J, Krizova A, Samy C, et al. (2011) Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 59: 721-730.
65. Osanto S, Qin Y, Buermans HP, Berkers J, Lerut E, et al. (2012) Genome-Wide MicroRNA Expression Analysis of Clear Cell Renal Cell Carcinoma by Next Generation Deep Sequencing. PLoS One 7: e38298.
66. The CCDS Database (2013) Current statistics for Homo sapiens for CCDS Release 12 Available: http://www.ncbi.nlm.nih.gov/projects/CCDS/CcdsBrowse.cgi?REQUEST=SHOW_STATISTICS.Accessed 2013 Sept 12.
67. Varela I, Tarpey P, Raine K, Huang D, Ong CK, et al. (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469: 539-542.
68. Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, et al. (2011) Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6: 692-702.
69. Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, et al. (2011) Increased methylation variation in epigenetic domains across cancer types. Nat Genet 43: 768-775.
70. Fearon ER, Vogelstein B, (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
71. Polascik TJ, Bostwick DG, Cairns P, (2002) Molecular genetics and histopathologic features of adult distal nephron tumors. Urology 60: 941-946.
72. TCGA (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519-525.
73. Kalari S, Pfeifer GP, (2010) Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet 70: 277-308.
74. Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, et al. (2003) Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 63: 8695-8699.
75. Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, et al. (2004) Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 64: 5511-5517.